Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 6136 | 4.48 |
09:34 ET | 500 | 4.49 |
09:36 ET | 6430 | 4.45 |
09:38 ET | 3600 | 4.46 |
09:39 ET | 1292 | 4.46 |
09:41 ET | 3917 | 4.41 |
09:43 ET | 1781 | 4.37 |
09:45 ET | 59698 | 4.3 |
09:48 ET | 3599 | 4.29 |
09:50 ET | 7283 | 4.32 |
09:52 ET | 2239 | 4.34 |
09:54 ET | 1000 | 4.32 |
09:56 ET | 592 | 4.32 |
09:57 ET | 5486 | 4.34 |
09:59 ET | 700 | 4.34 |
10:01 ET | 2721 | 4.35 |
10:03 ET | 3652 | 4.33 |
10:06 ET | 3184 | 4.3 |
10:08 ET | 1134 | 4.28 |
10:10 ET | 1696 | 4.254 |
10:12 ET | 9038 | 4.23 |
10:14 ET | 7387 | 4.255 |
10:15 ET | 2211 | 4.255 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 507.3M | -2.2x | --- |
Iteos Therapeutics Inc | 528.1M | -3.8x | --- |
Mind Medicine (MindMed) Inc | 508.1M | -2.4x | --- |
Third Harmonic Bio Inc | 513.5M | -16.3x | --- |
Allogene Therapeutics Inc | 500.1M | -1.3x | --- |
Lyell Immunopharma Inc | 520.1M | -1.6x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $507.3M |
---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.